CLOZABEN Trademark

Trademark Overview

On Wednesday, May 9, 2018, a trademark application was filed for CLOZABEN with the United States Patent and Trademark Office. The USPTO has given the CLOZABEN trademark a serial number of 87914130. The federal status of this trademark filing is REGISTERED as of Tuesday, March 30, 2021. This trademark is owned by SyneuRx International (Taiwan) Corp.. The CLOZABEN trademark is filed in the Pharmaceutical Products category with the following description:

Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical reagents for medical or veterinary purposes; Sodium salts for medical purposes
clozaben

General Information

Serial Number87914130
Word MarkCLOZABEN
Filing DateWednesday, May 9, 2018
Status700 - REGISTERED
Status DateTuesday, March 30, 2021
Registration Number6303592
Registration DateTuesday, March 30, 2021
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 12, 2021

Trademark Statements

Goods and ServicesTherapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical reagents for medical or veterinary purposes; Sodium salts for medical purposes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 18, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSyneuRx International (Taiwan) Corp.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW
Party NameSyneuRx International (Taiwan) Corp.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW
Party NameSyneuRx International (Taiwan) Corp.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW

Trademark Events

Event DateEvent Description
Saturday, May 12, 2018NEW APPLICATION ENTERED
Friday, May 18, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 30, 2018ASSIGNED TO EXAMINER
Wednesday, September 5, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 19, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 9, 2018PUBLISHED FOR OPPOSITION
Tuesday, October 9, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 4, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 14, 2019SOU TEAS EXTENSION RECEIVED
Tuesday, May 14, 2019SOU EXTENSION 1 FILED
Tuesday, May 14, 2019SOU EXTENSION 1 GRANTED
Thursday, May 16, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 7, 2019SOU TEAS EXTENSION RECEIVED
Thursday, November 7, 2019SOU EXTENSION 2 FILED
Thursday, November 7, 2019SOU EXTENSION 2 GRANTED
Saturday, November 9, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 11, 2020SOU TEAS EXTENSION RECEIVED
Monday, May 11, 2020SOU EXTENSION 3 FILED
Monday, May 11, 2020SOU EXTENSION 3 GRANTED
Wednesday, May 13, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 24, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, July 24, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, July 24, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, July 24, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, July 24, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, July 24, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, October 1, 2020TEAS PETITION TO AMEND BASIS RECEIVED
Monday, November 2, 2020ASSIGNED TO EXAMINER
Tuesday, December 1, 2020ASSIGNED TO PETITION STAFF
Wednesday, December 2, 2020PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Wednesday, December 2, 2020ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
Tuesday, December 1, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, December 1, 2020SOU EXTENSION 4 FILED
Tuesday, December 1, 2020SOU EXTENSION 4 GRANTED
Thursday, December 3, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 9, 2020NOTICE OF ALLOWANCE CANCELLED
Wednesday, December 9, 2020CASE RETURNED TO EXAMINATION
Wednesday, December 23, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 12, 2021PUBLISHED FOR OPPOSITION
Tuesday, January 12, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 30, 2021REGISTERED-PRINCIPAL REGISTER
Monday, March 30, 2026COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

clozaben disorder disorders namely purposes medical other bipolar central nervous impairment